Figure 1.

Effects of MKT-077 derivatives in TT and MZ-CRC-1 cells. (A) TT cells in 24-well plates were treated with serially increasing doses of MKT-077 and YM-08 for 48 h. Cells were then allowed to recover in drug-free fresh medium for 48 h, prior to determining cell viability by MTT assay, as described in the Materials and Methods. Data (mean ± SEM, n = 3) are expressed as the percentage of vehicle-treated control. The IC₅₀ values were calculated by PRISM. (B) Western blot analysis of total lysates of TT cells treated with MKT-077 and YM-08 for 48 h. β-actin is the control for equal protein loading. Equal volume of DMSO was used as the vehicle control. Blots are representative of two independent experiments. (C) IC₅₀ analysis in TT and MZ-CRC-1 cell cultures treated with indicated inhibitors for 72 h. Cell viability was determined by MTT assay. Data (mean ± SEM, n = 3) are expressed as the percentage of vehicle-treated control. (D) IC₅₀ analysis in TT and MZ-CRC-1 cell cultures treated with indicated inhibitors for 72 h. Cell viability was determined by MTT assay. Data (mean ± SEM, n = 3) are expressed as the percentage of vehicle-treated control. 95% Confidence Intervals in TT were 1.474 to 1.772 (JG-98), 0.848 to 1.019 (JG-194), 2.095 to 2.541 (JG-231), 1.315 to 1.653 (JG-294), 1.785 to 2.052 (JG-345), and 2.261 to 2.758 (MKT-077). While, 95% Confidence Intervals in MZ-CRC-1 were 6.070 to 14.54 (JG-98), 1.592 to 3.047 (JG-194), 5.917 to 12.80 (JG-231), 14.11 to 28.09 (JG-294), 10.92 to 20.06 (JG-345), and 29.85 to 128.4 (MKT-077).